Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Primary care is key in managing PCOS, focusing on lifestyle changes and medications like birth control and metformin.

This review examines treatment options for PCOS, highlighting the importance of managing symptoms and patient counseling, and reports no new clinical results.

This study examined serum PSA levels in women with androgenetic alopecia to evaluate their potential as a marker for androgen effects on target organs.

In this study, all stereoisomers of cyoctol were synthesized and tested, revealing that contrary to initial patent claims, cyoctol does not function as an anti-androgen.

This study found that both combined therapy with goserelin and oral contraceptives, and oral contraceptives alone, significantly reduced hair diameter in severe hirsutism without a significant difference between treatments.

In this study, patients with varying severities of acne, seborrhoea, and hirsutism responded differently to Cyproteronacetate and Ethinyloestradiol treatment, with improvement rates dependent on symptom severity and treatment duration.

This review covers cross-sex hormone therapy for gender dysphoria, noting improvements in psychological symptoms and quality of life but lacking definitive long-term safety data.

This study reports that spironolactone has shown effectiveness in improving hair density and reducing shedding in female pattern hair loss, particularly for women with hyperandrogenism, though benefits often diminish after stopping treatment.

This review discusses the role of antiandrogenic gestagens in treating androgen-dependent skin disorders and highlights the need for dermatologists to collaborate with endocrinologists and gynecologists for effective management.

This case report describes a 45-year-old woman who developed Cushing's syndrome and hirsutism after using topically applied desoximetasone (Topicorte).

In this study, spironolactone was found to be a safe and effective treatment for acne in women over 25 with abnormal hormone levels, while younger women with normal hormone levels showed less response.

In this case study, drospirenone use masked the diagnosis of a rare form of congenital adrenal hyperplasia, suggesting a possible delay in detecting underlying endocrinopathies.

This study provides a guideline for the safe and effective use of testosterone in women with hypoactive sexual desire disorder, recommending systemic transdermal testosterone for appropriate candidates while highlighting the importance of informed consent and monitoring due to unestablished long-term safety.

This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.

This study found that topically administered spironolactone in healthy volunteers resulted in no detectable systemic absorption or changes in related hormone levels over 72 hours, indicating local effect only.

This case report describes two women experiencing hormonally associated vestibulodynia and female arousal disorder, potentially linked to the use of spironolactone for androgen-mediated cutaneous disorders.

This study found that dexamethasone effectively suppressed DHEAS levels in women with elevated levels using much lower doses than previously thought, without significant adverse effects.

This study found that in women with acne vulgaris, lower serum levels of 3α-androstanediol-glucuronide suggest reduced 5α-reductase activity compared to controls, indicating that 5α-reductase inhibitors may not be effective for acne treatment.

This study found that compound 2g inhibits steroid sulfatase effectively without exhibiting estrogenic activity, making it a promising candidate for breast cancer treatment.

This study found that oral spironolactone is generally well tolerated and may be effective for treating female-pattern hair loss, with improvements in hair regrowth stability as measured by Sinclair scores.

This article discusses the underutilization of spironolactone in dermatology for conditions like acne, highlighting its potential benefits and good safety profile, but reports no new clinical findings.

This in-silico study identified several compounds as potential Vitamin D Receptor agonists, with Dolichosterone showing the strongest binding energy.

This study found that androsterone glucuronate (ADT-G) was the only androgenic metabolite sensitive to detecting differences between adult women with acne and controls, and its levels decreased with systemic treatment.

The estradiol valerate/dienogest oral contraceptive helps with heavy periods, may improve acne and symptoms in PCOS, and doesn't affect sexual function.

This study found that spironolactone directly inhibits 5 alpha-reductase activity in hirsute women, resulting in decreased conversion of testosterone to dihydrotestosterone, which may contribute to its therapeutic effects.

This study reports that spironolactone, a potassium-sparing diuretic with antiandrogenic activity, effectively improves hair density, reduces shedding, and stabilizes symptoms in female pattern hair loss, though symptoms often recur after discontinuation, suggesting the need for sustained therapy.

This study concluded that serum Adiol-G levels generally parallel testosterone levels and, therefore, do not effectively serve as a marker of peripheral androgen excess in women with androgenic symptoms.